Fresenius SE, Europe’s biggest publicly traded health-care provider, is weighing a bid for US generic drugmaker Akorn Inc., according to Bloomberg News, citing people familiar with the matter said.
The companies are in discussions, though no final decisions have been made, the people said, asking not to be identified as the deliberations are private.
Akorn could complement Fresenius’s Kabi medicines division, which specializes in intravenous drugs, and accounts for about a fifth of the company’s revenue. Lake Forest, Illinois-based Akorn makes branded and generic versions of ophthalmic, injectable and non-injectible drugs with manufacturing facilities in the U.S. and outside the country. Its brand-name drugs include asthma treatment Xopenex and heart medicine Akten. Last year, the company’s sales totaled $1.05 billion. It also has a consumer-health division that makes up about 6 percent of its total sales.